Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Liquid Biopsy Demonstrates Prognostic Potential in Metastatic TNBC
Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.
Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer
February 20th 2018Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).
Dr. Davids Discusses the Results of Ibrutinib Plus FCR in CLL
February 5th 2018Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses results of a study combining ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in patients with chronic lymphoctic leukemia (CLL).
Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer
June 29th 2017Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Dr. Farago on Opportunities to Investigate Biomarkers for Small Cell Lung Cancer
May 31st 2017Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).
Pembrolizumab Demonstrates Durable Response in PD-L1+ Endometrial Cancer
Results from the KEYNOTE-028 study showed that pembrolizumab (Keytruda) was associated with a median duration of response of 6 months and a 6-month progression-free survival rate of 40.4% in women with advanced PD-L1–positive endometrial cancer.
Dr. George on Efficacy With PD-1 Inhibitor in Uterine Leiomyosarcoma
May 2nd 2017Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.